This surgery is ideal for patients who may be deemed inoperable or at high risk for open heart surgery. For patients like Ms.

The FDA approved the Evoque tricuspid valve replacement system as the first transcatheter treatment for tricuspid regurgitation (TR), Edwards Lifesciences announced. Evoque gained an indication for ...

In order to understand tricuspid regurgitation, it helps to understand the basic anatomy of your heart. Your heart is divided into four sections called chambers. The upper chambers are the left atrium ...

FDA staff questioned the evidence for clinical benefit with the TriClip G4 transcatheter edge-to-edge repair (TEER) system for severe tricuspid regurgitation (TR) in documents released ahead of the ...

Edwards Lifesciences received a CE mark for what it says is the world’s first valve replacement system to receive regulatory approval to treat tricuspid regurgitation. The device, called Evoque, is ...

Tricuspid regurgitation is a condition divided into four stages based on several factors. Treatment for the condition varies based on the stage and symptoms and may include watchful waiting or, in ...

The investigational transfemoral EVOQUE tricuspid valve replacement system (Edwards Lifesciences) significantly reduced severity of tricuspid regurgitation and improved quality of life at 30 days in ...

A steady stream of structural trial data, approvals, reimbursement decisions, and real-world rollouts arrived in 2025.

PARIS — By assessing residual regurgitation after a transcatheter tricuspid valve repair with a four-grade rather than three-grade system, physicians can predict survival more accurately, reported ...

Tricuspid regurgitation develops when the tricuspid valve between the right atrium and right ventricle does not close properly. The tricuspid valve controls the blood flow from the right atrium to the ...